Long-term outcome in diabetic heart failure patients treated with cardiac resynchronization therapy

Cecilia Fantoni1, François Regoli, Ali Ghanem

  • 1Division of Cardiology, University Hospital, Magdeburg, Germany.

Insights

Diabetic patients with heart failure (HF) show similar positive outcomes to non-diabetic patients when treated with cardiac resynchronization therapy (CRT). This therapy improves function and survival rates for both groups, regardless of diabetes status.

Area of Science:

  • Cardiology
  • Diabetology
  • Medical Technology

Background:

  • Diabetes mellitus is a significant risk factor for heart failure (HF) complications.
  • Understanding treatment efficacy in diabetic HF patients is crucial.

Purpose of the Study:

  • To compare the effects of cardiac resynchronization therapy (CRT) on functional, structural, and long-term outcomes in diabetic versus non-diabetic HF patients.

Main Methods:

  • A comparative study of 141 diabetic and 214 non-diabetic HF patients receiving CRT.
  • Analysis of major adverse events (death, transplantation, LV assist device), hospitalizations, and CRT-D discharges.

Main Results:

  • CRT improved functional capacity, ventricular geometry, and neurohumoral balance in both groups over 34 months.
  • No significant differences in event-free survival, CRT-D interventions, or hospitalizations between diabetic and non-diabetic patients.
  • Multivariable analysis identified factors like NYHA class, LV ejection fraction, beta-blocker use, renal function, and lead presence, but not diabetes, as predictors of poor outcome.

Conclusions:

  • Diabetic HF patients experience comparable functional and survival benefits from CRT as non-diabetic patients.
  • CRT is an effective treatment option for improving outcomes in diabetic HF populations.
Abstract

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...